Skip to main content
AYTU BIOPHARMA, INC logo

AYTU BIOPHARMA, INC — Investor Relations & Filings

Ticker · AYTU ISIN · US0547548745 US Manufacturing
Open in API
Filings indexed 890 across all filing types
Latest filing 2025-06-05 Regulatory Filings
Country US United States of America
Listing US AYTU

About AYTU BIOPHARMA, INC

https://aytubio.com/

Aytu BioPharma, Inc. is a specialty pharmaceutical company focused on developing and commercializing novel therapeutics. The company concentrates on advancing innovative medicines for complex central nervous system (CNS) diseases, with a particular emphasis on treatments for Attention-Deficit/Hyperactivity Disorder (ADHD) and Major Depressive Disorder (MDD). Its business model involves identifying, acquiring, and commercializing new products to improve the quality of life for patients with unmet medical needs.

Recent filings

Filing Released Lang Actions
FORM S-1/A
Regulatory Filings Classification · 95% confidence The document is titled 'Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933' filed with the SEC. It is an amendment to a Form S-1 registration statement, which is used for registering securities for public offering. The text includes detailed exhibit listings and references to underwriting agreements, merger agreements, loan agreements, and other contracts. There is no indication that this is a full annual report, quarterly report, earnings release, or other financial performance report. Instead, it is a regulatory filing related to securities registration and amendments to that registration. The document is lengthy (15,000 characters) and contains detailed legal and contractual exhibits, consistent with an SEC registration statement amendment filing. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2025-06-05 English
Capital/Financing Update 2025
Capital/Financing Update Classification · 95% confidence The document is a letter addressed to the U.S. Securities and Exchange Commission regarding a request for acceleration of the effective date of a Registration Statement on Form S-1. It references securities regulations and underwriters, indicating it relates to a capital raising process. The document is short (1896 characters) and is a correspondence related to a registration statement, not the registration statement itself or a financial report. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2025-06-02 English
Regulatory Filings 2025
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-1. It is a correspondence related to a securities registration process, specifically under Rule 461 of the Securities Act of 1933. The document does not contain financial statements, audit information, or detailed report content. It is a regulatory communication related to the filing process rather than a report or announcement of financial results. Given its nature as a formal regulatory correspondence without substantive financial data or report content, it fits best under Regulatory Filings (RNS). The document length is short (1203 characters), and it is clearly a letter requesting an action from the SEC, not a report or announcement of a report publication.
2025-06-02 English
FORM S-1
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the U.S. Securities and Exchange Commission, dated June 2, 2025, for Aytu BioPharma, Inc. It includes a preliminary prospectus for an offering of common stock and prefunded warrants. The text contains detailed information about the securities being offered, underwriting, risk factors, use of proceeds, capitalization, dilution, management's discussion and analysis, and consolidated financial statements. This type of filing is a registration statement for a securities offering, which is a capital raising activity. Therefore, it fits the category of Capital/Financing Update filings, which cover updates on company fundraising and financing activities. The document is lengthy (15,000 characters) and contains substantive information about the offering, not just an announcement or notice, so it is not a Report Publication Announcement or Regulatory Filing. Hence, the correct classification is CAP (Capital/Financing Update).
2025-06-02 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 21, 2025, for Aytu BioPharma, Inc. It reports on the results of the 2025 Annual Meeting of stockholders, including voting results on director elections, an amendment to the equity incentive plan, appointment of the independent auditor, and an advisory vote on executive compensation. The document also includes information about the departure and election of directors and officers. The primary content is the submission of matters to a vote of security holders and changes in directors/officers. This matches the description of Board/Management Information filings, which cover announcements of changes in the company's board of directors or senior management, as well as voting results related to such changes. Although voting results are included, the document is not solely a declaration of voting results but also includes management changes and plan amendments. Therefore, the best classification is MANG (Board/Management Information). The document length (7382 characters) and content do not indicate it is a full Annual Report or an Earnings Release. It is not a Proxy Solicitation or a Report Publication Announcement. Hence, the classification is MANG with high confidence.
2025-05-21 English
FORM 10-Q
Interim / Quarterly Report Q3 2025
2025-05-14 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.